Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yarom, Nirit
NCT06478862: Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy	Recruiting	2	20	RoW	Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug	Lipomedix Pharmaceuticals Inc.	Cancer of Ovary, Pancreatic Ductal Adenocarcinoma	06/26	01/27
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments	Recruiting	N/A	2000	Europe, US, RoW	Plasma sample collection	OncoHost Ltd.	Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma	10/29	10/29

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yarom, Nirit
NCT06478862: Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy	Recruiting	2	20	RoW	Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug	Lipomedix Pharmaceuticals Inc.	Cancer of Ovary, Pancreatic Ductal Adenocarcinoma	06/26	01/27
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments	Recruiting	N/A	2000	Europe, US, RoW	Plasma sample collection	OncoHost Ltd.	Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma	10/29	10/29